You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
Clinical investigators have used Longhorn Vaccines and Diagnostics' qPCR approach in a study to detect M. tuberculosis DNA in the mouths of people at high risk for subclinical TB.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.